Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.
- Trial name
- NCT03382418
- Testing
- gp145 C.6980 Vaccine, Aluminum Hydroxide Adjuvant
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
Infection, Human Immunodeficiency Virus, HIV Infections
GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Human immuno deficiency virus 1 (HIV-1) infections continues to be a serious health threat throughout the world and development of medicines with new mechanism of action have an important role to play.
- Trial name
- NCT03231943
- Testing
- GSK3640254
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, HIV Seronegativity
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
AMENDED 8/94: To expand the safety and immunogenicity profile of MN rgp160 vaccine (Immuno-AG) by administering a higher dose (800 mcg) at 0, 1, 6, and 12 months and 0, 2, 8 and 14 months (these two schedules were compared in VEU…
- Trial name
- NCT00001043
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
Leveraging Family-Based Assets for Black MSM In House Ball Communities
Despite the advent of highly effective prevention tools such as HIV pre-exposure prophylaxis (PrEP), Black men who have sex with men (MSM) continue to have the highest incidence of new HIV diagnoses in the US but are least likely…
- Trial name
- NCT05071378
- Testing
- Our Family, Our Voices
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- State University of New York - Downstate Medical Center
HIV Infections
Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
Concomitant administration of recombinant human growth hormone (rhGH) may boost the expansion of immune reconstitution and broaden specific T cell responses not achievable by vaccination alone.
- Trial name
- NCT00287677
- Testing
- recombinant human Growth Hormone, Vaccination, HAART
- Where
- 2 sites in Spain
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infection
Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)
The purpose of the study is to evaluate whether mycophenolate mofetil (MMF) can treat the chronic hyperactivation of the immune system and (partly) prevent the decrease of the CD4+ T-cell count in chronically HIV-1 infected…
- Trial name
- NCT00120419
- Testing
- mycophenol mofetil (MMF, Cellcept®) 500 mg BID
- Where
- 5 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
HIV Infections
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions.
- Trial name
- NCT00000872
- Testing
- Abacavir sulfate, Nelfinavir mesylate, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV drugs.
- Trial name
- NCT00002407
- Testing
- Indinavir sulfate, Nevirapine, Lamivudine
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
HIV-1-infection
Impact of V106I on Resistance to Doravirine
Objective. To study the impact of V106I mutation in the reverse transcriptase of HIV-1 on the activity of Doravirine. Clinical hypotheses.
- Trial name
- V106IFC (NCT04894357)
- Testing
- Phenotypic resistance measure
- Volunteers
- 50 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
HIV-1 Infection
Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8558 monotherapy in anti-retroviral-naïve human immunodeficiency virus type 1 (HIV-1) infected participants.
- Trial name
- NCT03859739
- Testing
- MK-8558
- Where
- 2 sites in Germany, Romania
- Volunteers
- 21 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection, Adherence, Medication
Social Media for ART Adherence and Retention in Adolescents and Young Adults: the Vijana-SMART Study
The goal of this study is to investigate whether a virtual peer support group improves ART knowledge, adherence, and mental health in youth living with HIV in Kenya.
- Conditions
- HIV-1-infection, Adherence, Medication, Depression
- Trial name
- NCT05634265
- Testing
- Vijana-SMART
- Where
- Kenya
- Volunteers
- 55 people
- Sponsor
- University of Washington
HIV-1-infection
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine…
- Trial name
- NCT05495204
- Testing
- Ibalizumab
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Epividian
Sarcoma
Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection
RATIONALE: Herpesvirus is found in Kaposi's sarcoma lesions in most patients; it is therefore possible that the herpesvirus has a role in causing Kaposi's sarcoma.
- Trial name
- NCT00019240
- Testing
- cidofovir
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
HIV Infection
Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine
Recent studies have shown that patients receiving state-of-the-art treatment for HIV infection (highly active antiretroviral therapy, or HAART) show discordant responses to therapy-that is, they improve both clinically and…
- Trial name
- NCT00026676
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment
CAbotégravir LENacapavir DUal Long Acting
This study is a Phase II, prospective, single-arm, multicenter, non-randomized pilot study designed to evaluate the antiretroviral efficacy of lenacapavir in combination with cabotegravir injection over 48 weeks of follow-up in…
- Conditions
- HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment, CABOTEGRAVIR, LENACAPAVIR
- Trial name
- CALENDULA (NCT06657885)
- Testing
- his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
- Where
- 12 sites in France
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV-1 Infection
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
The primary objective of this study is to characterize the virologic efficacy of switching virologically suppressed participants on an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination…
- Trial name
- NCT03405935
- Testing
- B/F/TAF
- Where
- 25 sites in Belgium, France and 3 more
- Volunteers
- 86 people
- Sponsor
- Gilead Sciences
HIV-1, Treatment-naïve
Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals
Improved survival of people living with HIV has resulted in an increased occurrence of other comorbidities, such as cardiovascular, renal, bone and endocrine pathologies.
- Trial name
- BONBO (NCT03708289)
- Testing
- DXA scan, Achilles bone US, Medical body composition measurements
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- Universitair Ziekenhuis Brussel
Acquired Immunodeficiency Syndrome, HIV Infections
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
The primary objective of this study is to evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) versus ritonavir (RTV)-boosted atazanavir (ATV/r) plus…
- Trial name
- WAVES (NCT01705574)
- Testing
- E/C/F/TDF, ATV, RTV
- Where
- 99 sites in United States, Belgium and 10 more
- Volunteers
- 583 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
This study aimed to investigate the influence of hepatic insufficiency on the pharmacokinetics (PK) of doravirine (MK-1439). In Part 1, PK of doravirine in participants with moderate hepatic insufficiency was compared with that…
- Trial name
- NCT02089659
- Testing
- Doravirine
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.